Denver (Dec. 23, 2025) — The Colorado Department of Public Health and Environment, the Denver Department of Public Health and Environment, and Denver International Airport (DEN) are notifying the public of a possible measles exposure at Denver International Airport on Friday, Dec. 12. An out-of-state traveler with a confirmed case of measles traveled through DEN while infectious. For those traveling in the coming days and weeks, measles cases are occurring in parts of the U.S., with a higher lik

Researchers have created tiny metal-based particles that push cancer cells over the edge while leaving healthy cells mostly unharmed. The particles work by increasing internal stress in cancer cells until they trigger their own shutdown process. In lab tests, they killed cancer cells far more effectively than healthy ones. The technology is still early-stage, but it opens the door to more precise and gentler cancer treatments.Researchers led by RMIT University have developed extremely small part

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 24, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,022,062 shares of common stock (or pre-funded warrants in lieu

OTC Markets Quotation Update: Continued SEC Reporting and Planned Form S-1 Resale Registration ANAHEIM, CA - December 24, 2025 (NEWMEDIAWIRE) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has been notified that its common stock will transition from the OTCQB® Venture Market to the OTCID(TM) Market due to a technical eligibility matter related to OTCQB® public float requir

WEDNESDAY, Dec. 24, 2025 — Here’s a DIY prescription for women looking to do everything they can to prevent a broken hip: Drink tea, not coffee. A decade-long study of older women found that tea drinkers had slightly stronger bones than their coffee-consuming counterparts. "Even small improvements in bone density can translate into fewer fractures across large groups," said study co-leader Enwu Liu , a lecturer in the College of Medicine and Public Health at Flinders University in Australia. Liu

– In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF <50% – – On track to deliver full 12-week Part D readout in 2Q 2026 and Phase 3 start in 4Q 2026 – BOULDER, Colo., Dec. 24, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel oral, selective, cardiac sarcomere modul

Innovative angle-adaptive mechanical stabilization for large-bore catheter access CARLSBAD, CA, UNITED STATES, December 23, 2025 / EINPresswire.com / -- AVACEN , Inc., a leader in non-invasive and access-adjacent medical device innovation, today announced the issuance of a U.S. utility patent for its CATHeter STAbilization (CATHSTA™) device. CATHSTA™ is designed for high-acuity applications requiring secure large-bore vascular access, including transcatheter cardiac interventions, mechanical cir

SEONGNAM, South Korea, Dec. 23, 2025 /PRNewswire/ -- SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101 (API: SN-38) which is a polymer nanoparticle drug under phase 1b/2 clinical trial for small cell lung cancer. SNB-101 is the world's first nanoparticle anticancer drug that has formulated extremely insoluble SN-38 into polymer nanoparticles, which is

Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which $18 million was via private placement and concurrent registered direct offering on December 10, 2025, to strengthen cash position and support continued commercialization of LYMPHIR CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq

Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025 CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal year ended September 30, 2025. "2025 was a pivotal year for Citius as we successfully launched